The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma

Oncology Reports

Volumn 32, Issue 2, 2014, Pages 553-558

  Oishi, Tetsuro ^a   Itamochi, Hiroaki ^a   Kudoh, Akiko ^a   Nonaka, Michiko ^a   Kato, Misaki ^b   Nishimura, Mayumi ^b   Oumi, Nao ^b   Sato, Seiya ^a   Naniwa, Jun ^a   Sato, Shinya ^a   Shimada, Muneaki ^a   Kigawa, Junzo ^b   Harada, Tasuku ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Clear cell carcinoma; mTOR; Ovarian carcinoma; PI3K

Indexed keywords

DACTOLISIB; PROTEIN KINASE B; TEMSIROLIMUS; IMIDAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; QUINOLINE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL VIABILITY; CELLULAR DISTRIBUTION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; ONCOGENE K RAS; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA, CLEAR CELL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CYSTADENOMA, SEROUS; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; CELL LINE, TUMOR; CYSTADENOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903189432     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3268     Document Type: Article

References (30)

1. Scully RE: World Health Organization classification and nomenclature of ovarian cancer. J Natl Cancer Inst Monogr 42: 5-7, 1975.
2. McGuire V, Jesser CA and Whittemore AS: Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 84: 399-403, 2002. (Pubitemid 34211865)
3. Kennedy AW, Biscotti CV, Hart WR and Webster KD: Ovarian clear cell adenocarcinoma. Gynecol Oncol 32: 342-349, 1989. (Pubitemid 19074926)
4. Sugiyama T, Kamura T, Kigawa J, et al: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589, 2000. (Pubitemid 30331967)
5. Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083, 2010.
6. Nakayama K, Nakayama N, Kurman RJ, et al: Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 5: 779-785, 2006. (Pubitemid 44775134)
7. Zhang L, Huang J, Yang N, et al: Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 13: 5314-5321, 2007. (Pubitemid 47510355)
8. Campbell IG, Russell SE, Choong DYH, et al: Mutation of the PIK3CA gene in ovarian and breast cancer. Clin Cancer Res 64: 7678-7681, 2004. (Pubitemid 39446895)
9. Altomare DA, Wang HQ, Skele KL, et al: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23: 5853-5857, 2004. (Pubitemid 39093031)
10. Mabuchi S, Kawase C, Altomare DA, et al: mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 15: 5404-5413, 2009.
11. Kuo KT, Mao TL, Jones S, et al: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174: 1597-1601, 2009.
12. Maira SM, Stauffer F, Brueggen J, et al: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863, 2008.
13. Brachmann S, Hofmann I, Schnell C, et al: Specific apoptosis induction by the dual PI3K/mTOR inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci 106: 22299-22304, 2009.
14. Cho DC, Cohen MB, Panka DJ, et al: The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 16: 3628-3638, 2010.
15. Itamochi H, Kato M, Nishimura M, et al: Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2. Hum Cell 25: 111-115, 2012.
16. Itamochi H, Kato M, Nishimura M, et al: Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. Hum Cell 26: 121-127, 2013.
17. Itamochi H, Oishi T, Shimada M, et al: Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun. Clin Cancer Res 17: 4742-4750, 2011.
18. McIntyre AJ, Summersgill BM, Spendlove HE, et al: Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors. Neoplasia 7: 1047-1052, 2005. (Pubitemid 44430982)
19. Li VSW, Wong CW, Chan TL, et al: Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 5: 29, 2005.
20. Rauh-Hein AJ, Winograd D, Growdon WB, et al: Prognostic determinants in patients with uterine and ovarian clear carcinoma. Gynecol Oncol 125: 376-380, 2012.
21. Pectasides D, Fountzilas G, Aravantinos G, et al: Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 102: 285-291, 2006. (Pubitemid 44041640)
22. Miyazawa M, Yasuda M, Fujita M, et al: Therapeutic strategy targeting the mTOR-HIF-1α-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int 59: 19-27, 2009.
23. Itamochi H and Kigawa J: Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol 17: 430-440, 2012.
24. Efeyan A and Sabatini DM: mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 22: 169-176, 2010.
25. Harrington LS, Findlay GM, Gray A, et al: The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213-223, 2004. (Pubitemid 38988774)
26. Hartley D and Cooper GM: Role of mTOR in the degradation of IRS-1: regulation of PP2A activity. J Cell Biochem 85: 304-314, 2002. (Pubitemid 34274898)
27. Shoji K, Oda K, Kashiyama T, et al: Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One 7: e37431, 2012.
28. Montero JC, Chen X, Ocaria A, et al: Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Mol Cancer Ther 11: 1342-1352, 2012.
29. Santiskulvong C, Konecny GE, Fekete M, et al: Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 17: 2373-2384, 2011.
30. Rahman M, Nakayama K, Rahman MT, et al: Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol 43: 2197-2206, 2012.